Longeveron Inc. - LGVNR STOCK NEWS

Longeveron announces the completion of an investigator meeting for its ELPIS II Phase 2b clinical trial evaluating Lomecel-B™ as a treatment for Hypoplastic Left Heart Syndrome (HLHS), a rare pediatric heart defect. The trial is on track to complete enrollment of 38 patients by the end of 2024. Multiple nationally recognized children's treatment centers are participating. Phase 1 results showed a 100% transplant-free survival rate up to five years, compared to a 20% historical mortality rate. The trial aims to further evaluate the safety and efficacy of Lomecel-B™.

Longeveron, a clinical stage biotechnology company (NASDAQ: LGVN), announced its participation in the Emerging Growth Virtual Conference on June 12-13, 2024. The company will present on June 12 at 1:45 p.m. ET. The presentation will be webcast and accessible via the 'Events and Presentations' section of Longeveron's website. A replay will be available for 180 days post-conference. Questions can be submitted in advance or during the event.

Longeveron announced the launch of a new contract development and manufacturing business at its 15,000 sq. ft. GMP facility. The company signed its first contract with Secretome Therapeutics, a biotechnology firm working on neonatal mesenchymal stem cell-based therapeutics. This new business line is expected to generate $4-5 million in annual revenues. Longeveron aims to leverage its expertise and capacity to advance other pharmaceutical programs. The company continues to focus on its lead therapeutic candidate, Lomecel-B, for multiple conditions, including hypoplastic left heart syndrome and Alzheimer's disease.

Longeveron (NASDAQ: LGVN), a clinical-stage regenerative medicine biotech, will attend the BIO International Convention from June 3-6, 2024, in San Diego. At the event, Longeveron's management will meet with global pharma executives to discuss partnerships and strategic opportunities for its Alzheimer's disease program. Their lead candidate, Lomecel-B™, showed promising results in the Phase 2a CLEAR MIND trial, achieving primary safety and secondary efficacy endpoints. The trial indicated Lomecel-B™ could slow or prevent disease worsening in mild Alzheimer's patients. These findings will be presented at the 2024 Alzheimer's Association International Conference.

Longeveron (NASDAQ: LGVN) reported its Q1 2024 financials, highlighting significant progress in clinical trials for its lead candidate, Lomecel-B™. Notably, the Phase 2b trial for HLHS is on track for completion by 2024 end. Data from a Phase 2a Alzheimer's trial will be presented at the 2024 Alzheimer’s Conference, showing promising results. Financials show a 96% revenue increase to $0.5 million, driven by the Bahamas Registry Trial, and an 8% reduction in operating expenses. The company raised $11.4 million in April, bolstering its cash reserves to $2.3 million, which is expected to fund operations through Q4 2024.

Longeveron Inc. (NASDAQ: LGVN) announced planned transitions on its Board of Directors, welcoming Richard Kender, a retired Merck executive, and nominating Dr. Roger Hajjar and Neha Motwani as new board candidates. Existing directors Joshua Hare and Ursula Ungaro are up for re-election. Jeffrey Pfeffer and Cathy Ross have resigned voluntarily. These changes aim to bring in new, experienced leaders to enhance Longeveron's therapeutic development programs.

Longeveron Inc. (NASDAQ: LGVN) will report its first quarter 2024 financial results and provide a business update on May 14, 2024. The company, a clinical stage biotechnology firm focusing on regenerative medicines, will host a conference call and webcast at 5:00 p.m. ET the same day.

Longeveron Inc. (NASDAQ: LGVN) will be presenting at the Planet MicroCap Showcase on May 1-2, 2024. The presentation will take place on May 1, 2024, at 4:30 p.m. PT. Investors can register for 1x1 meetings with the company and attend the showcase in person at the Paris Hotel & Casino in Las Vegas, NV.

Longeveron Inc. (NASDAQ: LGVN) announced the closing of its warrant exercise offering and public offering, raising a total of $11.4 million in gross proceeds. The funding will be used to advance the HLHS program, including ongoing clinical trials for conditions like Alzheimer's disease and Aging-related Frailty. The Company issued new unregistered warrants to purchase up to 4,799,488 shares of Class A common stock, with gross proceeds of approximately $6.2 million from the warrant exercise offering and $5.2 million from the public offering. The net proceeds will support clinical and regulatory development, obtaining regulatory approvals, capital expenditures, working capital, and general corporate purposes.